Trevi Therapeutics Goes Up Against Cara In Itch
This article was originally published in Scrip
Trevi Therapeutics has announced positive Phase II/III results for its lead product nalbuphine ER tablets in treating uremic pruritus.
You may also be interested in...
Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.
The latest drug development news and highlights from our US FDA Performance Tracker.
A Vifor Fresenius joint venture will market Korsuva for CKD-associated pruritis to Fresenius dialysis centers in Europe, and also will do a co-promotion with Cara in the US that may provide a significant head start for the drug.